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Abstract
Although it occurs worldwide, hepatitis E virus (HEV) infection in developed countries is generally foodborne. HEV
infection is subclinical in most individuals. Although fulminant liver failure may occur, progression to chronic
hepatitis is rare. This study describes a 41-year-old man with liver cirrhosis caused by non-alcoholic steatohepatitis
and hepatocellular carcinoma within the Milan criteria. His liver function was classified as Child-Pugh grade C. Living
donor liver transplantation (LDLT) was performed, and he was discharged from the hospital on postoperative day
(POD) 22. However, his alanine aminotransferase concentration began to increase on POD 60 and HEV infection
was detected on POD 81. Retrospective assessments of stored blood samples showed that this patient became
positive for HEV RNA on POD 3. The liver donor was negative for anti-HEV antibodies and HEV RNA. However, the
platelet concentrate transfused into the liver recipient the day after LDLT was positive for HEV RNA. The patient
remained positive for HEV infection for 10 months. Treatment with 800 mg/day ribavirin for 20 weeks reduced HEV
RNA to an undetectable level. In conclusion, this report describes a patient infected with HEV through a blood
transfusion after LDLT, who progressed to chronic hepatitis probably due to his immunosuppressed state and was
treated well with ribavirin therapy.
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Background
Hepatitis E virus (HEV) is a member of the genus Ortho-
hepevirus within the family Hepeviridae [1]. Approxi-
mately 20 million persons per year worldwide are
estimated to be infected with HEV. Four major HEV ge-
notypes can infect humans. HEV genotypes 1 and 2 are
only found in humans, whereas HEV genotypes 3 and 4
are found in swine and other animals, infecting humans
in developed countries through consumption of food [2].
Hepatitis E was previously regarded as a cause of acute
hepatitis, with no progression to chronic hepatitis. More
recently, however, progression to chronic hepatitis has
been observed in immunocompromised hosts, including
patients receiving solid organ transplants [3], those
positive for human immunodeficiency virus (HIV) [4]
and patients receiving chemotherapy for hematological
malignancies [5].
Our group recently published the first nationwide survey
about HEV infection among Japanese liver transplant re-
cipients [6]. Two liver transplant recipients were diagnosed
with HEV infection after living donor liver transplantation
via blood transfusion. Here, we describe the clinical course
of the patient who remained positive for HEV and was
treated well with ribavirin therapy.
Case presentation
A 41-year-old man with a history of liver cirrhosis
caused by non-alcoholic steatohepatitis (NASH) and he-
patocellular carcinoma (HCC) within the Milan criteria
was referred to our hospital for possible living donor
liver transplantation (LDLT) from his healthy 35-year-
old brother. The patient was obese from childhood, with
a peak body weight of 140 kg. He had been treated for
HCC by radiofrequency ablation 2 years earlier and by
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transarterial chemoembolization 5 months earlier. La-
boratory data included white blood cell count 3320/mL,
hemoglobin 12.6 g/dL, platelet count 5.6 × 104/mL, total
protein 6.4 mg/dL, albumin 2.7 g/dL, creatinine
0.87 mg/dL, total bilirubin 3.7 mg/dL, aspartate amino-
transferase (AST) 91 U/L, alanine aminotransferase
(ALT) 53 U/L, sodium 137 mEq/L, ammonia, 135 mg/dL,
and prothrombin time 32 %. The patient was classified as
Child-Pugh grade C with 11 points, and his model for
end-stage liver disease score was 20. He was negative for
hepatitis B surface antigen and antibody to hepatitis C
virus. Tumor markers included α-fetoprotein 5.1 ng/mL
and PIVKA-II 10,848 U/mL.
Laparotomy revealed a cirrhotic liver and an enlarged
spleen. The recipient’s liver was removed, and the do-
nated right lobe graft was implanted. The graft weight
was 798 g, corresponding to 57.4 % of the recipient’s
standard liver weight. Splenectomy was also performed.
The total operating time was 819 min, and total blood
loss was 3450 mL. There are three hepatocellular carcin-
omas in the resected specimen. The largest tumor size
was 20 mm in diameter. Histological examination
showed a well-differentiated hepatocellular carcinoma
growing in trabecular and focally pseudo-glandular pat-
terns. The surrounding liver tissues showed micronodular
cirrhotic change with mild chronic inflammatory infiltrate
the fibrous stroma (A1F4) with 5 % macrovesicular steato-
sis, which was compatible with burn-out NASH.
On the day of surgery, the patient received transfu-
sions of 20 units of red blood cell concentrates, 12 units
of fresh frozen plasma, and 20 units of platelet concen-
trate. On postoperative day (POD) 1, he was transfused
with 16 units of fresh frozen plasma and 20 units of
platelet concentrate. Subsequent transfusions included
four units of fresh frozen plasma on POD 2, two units of
red blood cell concentrate on POD 9, and four units of
red blood cell concentrate on POD 13 (Table 1).
Following LDLT, immunosuppression was started, in-
cluding tacrolimus, mycophenolate mofetil, and steroids.
The patient was discharged from the hospital on POD
22. Treatment with mycophenolate mofetil was discon-
tinued on POD 32. His liver-enzyme became elevated
(AST 46 U/L, ALT 56 U/L, total bilirubin 0.5 mg/dL) on
POD 60. Immunosuppression was maintained including
tacrolimus to the trough of 10 to 15 ng/mL and prednis-
olone 5 mg/day. At the same time, nationwide survey to
clarify the presence of HEV infection after liver trans-
plant in Japan was started and his blood samples taken
on POD 81 showed positive for HEV RNA and IgG and
IgM antibodies to HEV. To determine the time of HEV
infection, stored blood samples taken just before trans-
plantation and on PODs 1, 3, 7, and 14 were assayed for
the presence of HEV RNA and anti-HEV antibodies.
Blood samples from the donor were also assayed to
determine whether infection was graft mediated. These
assays showed that the patient first became positive for
HEV RNA on POD 3, remaining positive thereafter. The
donor sample was negative for anti-HEV antibodies and
HEV RNA (Fig. 1).
Analysis of the route of infection
The transplantation protocol of our institution does not
permit patients to ingest raw meat or raw fish until
1 year after LDLT. This patient had not ingested such
foods after LDLT, precluding the likelihood of foodborne
infection with HEV.
Eliminating the possibilities of donor and foodborne
sources of HEV suggested that this patient may have
become infected through a blood transfusion. Assays of
the transfused samples, supplied by Fukuoka Prefecture
Red Cross Blood Center, showed that HEV RNA was
present in the platelet concentrate transfused into this
patient on POD 1 (lot number 5020364476).
Table 1 Details of blood transfusions
Date Content Units Lot number






















POD 2 FFP 4 5101362480
POD 9 RCC 2 5006268035
POD 13 RCC 2 5112254264
RCC 2 5112254256
LDLT living donor liver transplantation, RCC red cell concentrate, FFP fresh
frozen plasma, PC platelet concentrate, POD postoperative days
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Clinical significance of the HEV genotype
The genomic sequences of the HEV strain detected in
the patient and the transfused platelet concentrate were
compared. Sequences compared included a 326-nucleotide
(nt) 5′-terminal region of the open reading frame (ORF)1,
a 505-nt region of the proline-rich hinge (V) domain
within the ORF1, and a 412-nt region of the ORF2. The
two strains differed by one nt in the ORF1 and by two nts
in the V domain, but their ORF2 sequences were identical.
Phylogenetic analysis of the HEV strains, conducted
according to the previously described method [7], re-
vealed that the HEV strains in the transfused sample,
and the patient were both classifiable into genotype 3
(subgenotype 3b) (Fig. 2). These two isolates were clos-
est to an HEV strain (95.6 % identity) isolated from a
wild boar that had been captured in Saga Prefecture on
Kyushu Island of Japan. These findings suggested that
the source of infection was HEV strains circulating on
Kyushu Island, Japan.
Antiviral treatment
Treatment with steroids was decreased gradually and
discontinued on POD 150. Thereafter, immunosuppres-
sive therapy was done with tacrolimus monotherapy and
the dosage was reduced to the target trough of 5–10 ng/
mL. The patient remained positive for both HEV RNA
and anti-HEV antibodies on POD 284, more than
6 months after diagnosis of HEV infection. Although a
liver biopsy was not obtained, this patient was consid-
ered a chronic carrier of HEV. Treatment with ribavirin
800 mg/day was started on POD 327. AST and ALT
became normal on POD 382, and he became negative
for HEV RNA on POD 417. The therapy was done until
POD 467. HEV RNA remained negative on POD 536.
Discussion
Chronic hepatitis E is characterized by mild derange-
ment in liver enzymes, persistently detectable HEV RNA
in serum and stool for >3 months, delayed/absent HEV
seroconversion, and histological features of chronic viral
hepatitis, such as dense lymphocytic periportal infiltrates
with piecemeal necrosis [8]. Screening for HEV RNA in
the sera of liver transplant recipients showed that the
prevalence of HEV infection in Europe was <1 % [9, 10].
The inability to clear HEV viremia is directly related to
the degree of immunosuppression of these patients at
the time of infection. Therefore, infections that occur
shortly after transplantation and rejection episodes, and
when patients have low total lymphocyte counts, are
more likely to become chronic. Treatment with tacroli-
mus, as opposed to cyclosporine, was also shown to be a
risk factor for chronic HEV in posttransplant patients
[11]. Our immunosuppression strategy was initiated
using a protocol based on either tacrolimus (Prograf;
Astellas Pharma, Tokyo, Japan) or cyclosporine A
(Neoral; Novartis Pharma K.K., Tokyo, Japan) with ste-
roids with or without mycophenolate mofetil. The target
tacrolimus trough concentration was set at 10 ng/mL for
3 months after LDLT and 5–10 ng/mL thereafter. The
target trough concentration of cyclosporine A was set at
Fig. 1 Postoperative ALT (U/L) transition; anti-HEV IgA, anti-HEV IgM, and anti-HEV IgG concentrations (OD at 450 nm) and HEV-RNA titers (copies/mL)
in this patient. The patient became positive for HEV RNA on POD 3. Mildly abnormal ALT was observed on POD 60, with HEV RNA confirmed as being
persistently positive. Ribavirin therapy was started on POD 327. ALT normalized on POD 382 and HEV RNA became undetectable on POD 417. The
therapy was done until POD 467. HEV RNA remained negative on POD 536. IgA anti-HEV IgA, IgM anti-HEV IgM, IgG anti-HEV IgG, MMF mycophenolate
mofetil, PSL prednisolone, TAC tacrolimus
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250 ng/mL for 3 months after LDLT and 150–200 ng/
mL thereafter. Methylprednisolone was initiated on the
day of LDLT, after which the dosage was tapered and
prednisolone substituted for 7 days after LDLT. Prednis-
olone treatment was tapered and discontinued 6 months
after LDLT. Mycophenolate mofetil was beginning with
1–2 g/day on the day after LDLT; the dosage was
tapered and discontinued 6 months after LDLT. In this
case, immunosuppression including tacrolimus might
have influenced the chronicity of HEV infection.
Chronic HEV infection is frequently related to the
consumption of undercooked pork or, in some cases,
mussels or game meat [12]. Transmission of HEV via an
infected liver graft has also been reported [13]. Trans-
fused blood products are another potentially important
mode of acquisition. In the UK, it was recently estimated
that one in 2848 blood donors has hepatitis E viremia at
the time of donation [14]. The first case of HEV infec-
tion via a blood transfusion in Japan was reported in
2004 [15]. A nationwide survey of the prevalence of
HEV infection in Japan showed that 431 (3.4 %) of
12,600 donated blood samples were positive for anti-
HEV IgG [16]. Although all donated blood samples are
not checked for HEV, samples donated on Hokkaido
Fig. 2 Phylogenetic tree of HEV constructed based on the 412-nt ORF2 sequence of 44 HEV strains, showing that the KS-173 strain in this patient
was identical to the HEV strain (HEV5020364476) recovered from one of the transfused blood samples and shared the highest identity of 95.6 %
with an HEV strain (wbJSG1) isolated from a wild boar that had been captured in Saga Prefecture, Kyushu Island, Japan
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Island are assayed by PCR amplification of HEV specific
sequences, as the prevalence of acute hepatitis E is
higher in Hokkaido than elsewhere in Japan [17]. In the
present, screening of donated blood for HEV has only
been conducted in the Hokkaido area. Patients receiving
transfusion include many immunocompromised patients,
so screening of blood donors for HEV in other areas in
Japan is probably desirable.
Immunocompromised patients diagnosed with hepatitis
E should be closely followed up, with regular monitoring
of blood HEV RNA viral load, liver function tests, and
liver stiffness. Delay in the management of persistent
viremia should be minimized due to the potentially rapid
onset of irreversible liver injury. Reduction in immuno-
suppression should be considered for patients with HEV
viremia persisting for more than 3 months. In a previous
study, reduction in immunosuppression, especially of
calcineurin inhibitor, led to HEV clearance in one third of
patients [11]. The remaining two third patients required
antiviral therapy. If viremia still persists, treatment with
ribavirin should be considered, as ribavirin monotherapy
results in a sustained virological response rate of 78 % in
patients with chronic hepatitis E [18].
Conclusions
This study describes a patient who was infected with
HEV after LDLT and progressed to chronic hepatitis.
HEV was transmitted to this patient by a blood transfu-
sion following LDLT. Treatment with ribavirin was
successful.
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